They "recommended that companies be required to conduct additional
studies to assess the cardiovascular risk of their products for patients with age-related low
testosterone".
Seems to be a contingent risk here that didn't exist beforehand to me.
"The panel voted in favour of changing language in the products' labels to
restrict the intended uses of the drugs, particularly in relation to age-related low
testosterone."
Wonder if insurers will be tightening their requirements for coverage - I would assume so - that might cost dollars.
Risk is risk - good luck - might be back at $2 soon, or $1 soon - I have no idea tbh. Look forward to trading it in either direction if I can work it out - lol.
Add to My Watchlist
What is My Watchlist?
